217 related articles for article (PubMed ID: 15384026)
1. Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Phakdeekitcharoen B; Leelasa-nguan P
Am J Kidney Dis; 2004 Oct; 44(4):738-46. PubMed ID: 15384026
[TBL] [Abstract][Full Text] [Related]
2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
[TBL] [Abstract][Full Text] [Related]
3. The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
Jearnsujitwimol V; Eiam-Ong S; Kanjanabuch T; Wathanavaha A; Pansin P
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S188-95. PubMed ID: 17044472
[TBL] [Abstract][Full Text] [Related]
4. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
Frimodt-Møller M; Høj Nielsen A; Strandgaard S; Kamper AL
Nephrol Dial Transplant; 2010 Mar; 25(3):842-7. PubMed ID: 19903661
[TBL] [Abstract][Full Text] [Related]
7. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
Kanno Y; Takenaka T; Nakamura T; Suzuki H
Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
[TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
[TBL] [Abstract][Full Text] [Related]
9. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil.
Saito M; Nakayama D; Takada M; Hirooka K; Yasumura Y
J Clin Pharm Ther; 2006 Dec; 31(6):535-40. PubMed ID: 17176359
[TBL] [Abstract][Full Text] [Related]
10. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
11. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Kincaid-Smith P; Fairley KF; Packham D
Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
[TBL] [Abstract][Full Text] [Related]
13. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
Young JB; Dunlap ME; Pfeffer MA; Probstfield JL; Cohen-Solal A; Dietz R; Granger CB; Hradec J; Kuch J; McKelvie RS; McMurray JJ; Michelson EL; Olofsson B; Ostergren J; Held P; Solomon SD; Yusuf S; Swedberg K;
Circulation; 2004 Oct; 110(17):2618-26. PubMed ID: 15492298
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Desai AS; Swedberg K; McMurray JJ; Granger CB; Yusuf S; Young JB; Dunlap ME; Solomon SD; Hainer JW; Olofsson B; Michelson EL; Pfeffer MA;
J Am Coll Cardiol; 2007 Nov; 50(20):1959-66. PubMed ID: 17996561
[TBL] [Abstract][Full Text] [Related]
15. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
Robles NR; Fernandez Carbonero E; Romero B; Sánchez Casado E; Cubero JJ
Cardiovasc Ther; 2009; 27(2):101-7. PubMed ID: 19426247
[TBL] [Abstract][Full Text] [Related]
16. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin receptor blockade with candesartan in heart failure: findings from the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
Ostergren JB
J Hypertens Suppl; 2006 Mar; 24(1):S3-7. PubMed ID: 16601570
[TBL] [Abstract][Full Text] [Related]
18. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
19. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
20. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]